Brandon Capital

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing treatments for respiratory diseases. Originating as a spinout from the Telethon Kids Institute in Perth, the company advances inhaled therapies and antibiotic approaches to combat lung infections, notably in cystic fibrosis. Its product strategy includes an inhaled therapy for cystic fibrosis and an antibiotic program that combines tobramycin with an adjuvant to disrupt bacterial biofilms in the lung, improving antibiotic efficacy. Respirion engages in clinical development partnerships to advance its programs in Australia and the United States, supporting trials through collaborations with life science investors and disease foundations. The company’s approach aims to address the challenges of antibiotic resistance and persistent lung infections by delivering targeted therapies directly to the respiratory tract.

Founded in 2017, Cincera Therapeutics specializes in the discovery and development of small molecule drugs targeting difficult-to-treat inflammatory and fibrotic conditions associated with obesity, metabolic disorders, and cancer.

MycRx is a biotechnology company focused on developing novel cancer therapies. Utilizing proprietary hit identification technology, the company targets inhibitors of cMyc, a protein overexpressed in over 50% of human cancers. Headquartered in Melbourne, Australia, MycRx collaborates with esteemed institutions such as Peter MacCallum Cancer Centre and CSIRO.

Aravax is an early-stage biotechnology company developing peanut allergy therapies. It uses proprietary technology to reset the immune system to tolerate peanuts without triggering allergic reactions, aiming to provide a safe and rapidly effective treatment. The company was founded in 2015 through the acquisition of intellectual property developed by Alfred Health and Monash University and is headquartered in Melbourne, Australia.

OncoRes Medical develops an intraoperative imaging technology designed to assist surgeons in identifying tumors and healthy tissues during surgery. The company, based in Perth, Western Australia, collaborates with leading researchers at the University of Western Australia and breast cancer surgeons to develop this patent-protected technology.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Founded in 2017, Cincera Therapeutics specializes in the discovery and development of small molecule drugs targeting difficult-to-treat inflammatory and fibrotic conditions associated with obesity, metabolic disorders, and cancer.

Q-Sera develops innovative blood collection tubes using synthetically produced snake venom-derived pro-coagulant proteins. These tubes accelerate blood clotting, rapidly producing high-quality serum for biochemical analysis, thereby enhancing laboratory efficiency and patient care.

Certa Therapeutics, established in 2017 and headquartered in Melbourne, Australia, is a biotechnology company specializing in the development of precision medicines for fibrotic diseases, with a primary focus on kidney disorders. The company employs genetic analysis to identify patients at risk of developing kidney fibrosis, a precursor to end-stage kidney failure. Certa's drug pipeline targets a key receptor driving kidney fibrosis, aiming to halt or reverse the scarring process and prevent the need for dialysis or transplantation. Currently in the clinical stage, the company's mission is to transform the treatment landscape for fibrotic diseases by enabling early intervention and improving patient outcomes.

Global Kinetics Corporation Limited is a Melbourne-based company that specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. Founded in 2007, it focuses on the development of innovative solutions for monitoring, quantifying, and reporting the movement symptoms associated with neurological diseases. The company's flagship product, the PKG Data Logger, is a wrist-worn device designed to automatically capture movement data, thereby aiding healthcare professionals in diagnosing and treating movement disorders. The technology originated from research conducted by Professor Malcolm Horne and Dr. Rob Griffiths at the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research team in Australia.

Founded in 2017, Cincera Therapeutics specializes in the discovery and development of small molecule drugs targeting difficult-to-treat inflammatory and fibrotic conditions associated with obesity, metabolic disorders, and cancer.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Elastagen is a clinical-stage medical company focused on developing products based on human protein tropoelastin, a vital component for tissues that require elasticity, such as skin and blood vessels. The company has created a synthetic version of elastin that mirrors the natural protein found in the human body, allowing for innovative applications in skin rejuvenation, scar remodeling, and tissue repair. Elastagen's offerings include injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic purposes, aimed at helping patients maintain skin elasticity and suppleness. Founded through the acquisition of intellectual property from research conducted by Prof Weiss at the University of Sydney, Elastagen has attracted significant investment from both Australian and international life science venture capital groups. Its operations have grown from Australia to include production facilities in Europe and clinical activities in the UK.

Aravax is an early-stage biotechnology company developing peanut allergy therapies. It uses proprietary technology to reset the immune system to tolerate peanuts without triggering allergic reactions, aiming to provide a safe and rapidly effective treatment. The company was founded in 2015 through the acquisition of intellectual property developed by Alfred Health and Monash University and is headquartered in Melbourne, Australia.

Global Kinetics Corporation Limited is a Melbourne-based company that specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. Founded in 2007, it focuses on the development of innovative solutions for monitoring, quantifying, and reporting the movement symptoms associated with neurological diseases. The company's flagship product, the PKG Data Logger, is a wrist-worn device designed to automatically capture movement data, thereby aiding healthcare professionals in diagnosing and treating movement disorders. The technology originated from research conducted by Professor Malcolm Horne and Dr. Rob Griffiths at the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research team in Australia.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.

MycRx is a biotechnology company focused on developing novel cancer therapies. Utilizing proprietary hit identification technology, the company targets inhibitors of cMyc, a protein overexpressed in over 50% of human cancers. Headquartered in Melbourne, Australia, MycRx collaborates with esteemed institutions such as Peter MacCallum Cancer Centre and CSIRO.

Heart Metabolics Limited is a pharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, making it harder for blood to leave the heart and often leading to heart failure or sudden death. With over 100,000 cases in the United States alone, HCM can be particularly severe in young adults and athletes. Current cardiovascular drugs do not help all patients, highlighting a significant medical need. Heart Metabolics is addressing this by developing perhexiline, an approved drug in Australia and New Zealand for angina, as a therapeutic for all types of HCM. The company plans to conduct clinical trials in the U.S. and seek FDA approval for perhexiline as an orphan drug, which it has already designated.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

G I Therapies is a Melbourne-based company founded in 2012 that specializes in developing non-invasive medical devices aimed at treating gastrointestinal motility disorders. The company's primary focus is on chronic constipation, a condition affecting both adults and children, as well as related issues such as irritable bowel syndrome with constipation and gastroparesis. By commercializing innovative technologies, G I Therapies seeks to enhance the quality of life for patients suffering from these disorders, providing effective solutions that promote better gastrointestinal health.

Q-Sera develops innovative blood collection tubes using synthetically produced snake venom-derived pro-coagulant proteins. These tubes accelerate blood clotting, rapidly producing high-quality serum for biochemical analysis, thereby enhancing laboratory efficiency and patient care.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Vaxxas is a biotechnology company developing needle-free vaccination technology. It uses proprietary dry-coating technology to eliminate or significantly reduce the need for vaccine refrigeration, easing storage and transportation logistics.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, specializing in the manufacture of portable point-of-care devices for both medical and veterinary markets. Established in 1998, the company is known for its flagship product, the SignosRT, which includes a bladder scanner that utilizes ultrasound technology to detect bladder presence and calculate volume, as well as a handheld ultrasound device designed to assist clinicians during examinations. Signostics aims to revolutionize healthcare practices by providing fast and affordable ultrasound solutions that can be easily integrated into clinical settings. The company has expanded its reach internationally, particularly entering the U.S. market in 2008, and offers its products through a network of distributors. Signostics is committed to enhancing medical practices across various fields, including internal medicine, family practice, and physical therapy.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, specializing in the manufacture of portable point-of-care devices for both medical and veterinary markets. Established in 1998, the company is known for its flagship product, the SignosRT, which includes a bladder scanner that utilizes ultrasound technology to detect bladder presence and calculate volume, as well as a handheld ultrasound device designed to assist clinicians during examinations. Signostics aims to revolutionize healthcare practices by providing fast and affordable ultrasound solutions that can be easily integrated into clinical settings. The company has expanded its reach internationally, particularly entering the U.S. market in 2008, and offers its products through a network of distributors. Signostics is committed to enhancing medical practices across various fields, including internal medicine, family practice, and physical therapy.

Fibrotech Therapeutics is a biopharmaceutical company based in Wonga Park, Australia, focused on developing novel drug candidates aimed at treating fibrosis associated with various chronic conditions. Established in 2006, the company is dedicated to addressing unmet medical needs in diseases such as diabetic nephropathy, kidney disorders, heart failure, pulmonary fibrosis, and arthritis. Through its innovative approach, Fibrotech Therapeutics seeks to provide effective therapeutic options for patients suffering from these debilitating conditions.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.